Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA

Clinical Infectious Diseases

Volumn 60, Issue 11, 2015, Pages 1715-1721

  Laanani, Moussa ^a,b   Ghosn, Jade ^c,d   Essat, Asma ^a   Melard, Adeline ^e   Seng, Rémonie ^a,b   Gousset, Marine ^e   Panjo, Henri ^a   Mortier, Emmanuel ^f   Girard, Pierre Marie ^g,h,i   Goujard, Cécile ^a,j   Meyer, Laurence ^a,b   Rouzioux, Christine ^d,e  

^a INSERM   (France)

^b BICÊTRE HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f HÔPITAL LOUIS MOURIER   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

cohort; HIV 1 DNA reservoir; primary HIV infection; remission; slopes of HIV DNA decay

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CELL DNA; VIRUS DNA; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TIME TO TREATMENT; TREATMENT DURATION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; PROCEDURES; PROVIRUS; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROVIRUSES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84930385984     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ171     Document Type: Article

References (40)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf. Accessed 3 March 2015.
2. Morlat P. Prise en charge médicale des personnes vivant avec le VIH. B: Ministère des Affaires sociales et de la Santé, La Documentation Française, 2013.
3. Ghosn J, Deveau C, Chaix M-L, et al. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother 2010; 65:741-8.
4. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-22.
5. Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42:709-15.
6. Tierney C, Lathey JL, Christopherson C, et al. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 2003; 187:144-8.
7. Kostrikis LG, Touloumi G, Karanicolas R, et al. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002; 76:10099-108.
8. Rouzioux C, Hubert J-B, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005; 192:46-55.
9. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41:1053-6.
10. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
11. Avettand-Fenoel V, Flandre P, Chaix M-L, et al. Impact of 48 week lopinavir/ ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial. J Antimicrob Chemother 2010; 65:1005-7.
12. Lambert-Niclot S, Flandre P, Valantin M-A, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ ritonavir monotherapy. J Infect Dis 2011; 204:1211-6.
13. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune- based therapies. J Infect Dis 2003; 188:1426-32.
14. Assoumou L, Weiss L, Picketty C, et al. A low HIV-DNA level in peripheral blood mononuclear cells at ART interruption predicts a higher probability of maintaining plasma viral load <400 copies/mL. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3-6 March 2013.
15. Besson GJ, Lalama CM, Bosch RJ, et al. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. B Infect Dis 2014; 59:1312-21.
16. Viard J-P, Burgard M, Hubert J-B, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS Lond Engl 2004; 18:45-9.
17. Hocqueloux L, Avettand-Fènoël V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013; 68:1169-78.
18. Buzon MJ, Martin-Gayo E, Pereyra F, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. B Virol 2014; 88:10056-65.
19. Okoye A, Rohankhedkar M, Reyes M, et al. Treatment in acute SIV infection limits the size and distribution of the viral reservoir. In: 21st Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, 3-6 March 2014.
20. Whitney JB, Hill AL, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014; 512:74-7.
21. Luteijn R, Sciaranghella G, van Lunzen J, et al. Early viral replication in lymph nodes provides HIV with a means by which to escape NK-cellmediated control. Eur J Immunol 2011; 41:2729-40.
22. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med 2012; doi:10.1101/cshperspect.a006965.
23. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719-33.
24. Krastinova E, Seng R, Yéni P, et al. Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts. PLoS One 2013; 8:e71473.
25. Avettand-Fènoël V, Boufassa F, Galimand J, Meyer L, Rouzioux C. HIV- 1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is. B Clin Virol 2008; 42:399-404.
26. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. 2nd ed. Hoboken, NJ: Wiley-Blackwell, 2011.
27. Adalid-Peralta L, Godot V, Colin C, et al. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection. J Leukoc Biol 2008; 83:1060-7.
28. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-9.
29. Ngo-Giang-Huong N, Deveau C, Da Silva I, et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001; 15:665-73.
30. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000; 14:2805-12.
31. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-41.
32. Appay V, van Lier RAW, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008; 73:975-83.
33. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-84.
34. Chéret A, Bacchus C, Mélard A, et al. Early HAART in primary HIV infection protects TCD4 central memory cells and can induce HIV remission. In: 21st Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, 3-6 March 2014.
35. Thornhill J, Inshaw J, Oomeer S, et al. Enhanced normalisation of CD4/ CD8 ratio with early antiretroviral therapy in primary HIV infection. J Int AIDS Soc 2014; 17:19480.
36. Okulicz JF, Le TD, Agan BK, et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med 2015; 175:88-99.
37. Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog 2014; 10:e1004543.
38. Koelsch KK, Liu L, Haubrich R, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008; 197:411-9.
39. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 9: e1003174.
40. Williams JP, Hurst J, Stöhr W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife 2014; 3:e03821.